Tough Times In Europe For Gene Therapy Companies
Zynteglo Failure Will Be Worrying For Fellow Gene Therapy Developers
bluebird bio's decision to wind down commercial initiatives for its gene therapy business in Europe is a blow for the sector in the region as a whole.
